

A series of overlapping, wavy teal lines that flow across the top and left side of the page, creating a sense of movement and depth.

**Exane Convertibles
Indices (ECI)**

A solid teal vertical bar located on the left side of the page, positioned to the left of the main title.

NOTICE OF INDEX TERMINATION

29 August 2022

NOTICE OF INDEX TERMINATION

Relating to:

**ECI-Europe
ECI-Europe Ex USD
ECI Euro
ECI-Euro IG
Top-ECI
ECI-MidCap Euro
ECI-MidCap Euro Capi
ECI-Europe EUR-H
ECI-Europe USD-H
ECI-Europe CHF-H
(together the “Impacted Indices”)**

Following the acquisition of Exane by BNP Paribas and as part of the process of integration, a strategic review of all indices administered by Exane Derivatives SNC (the “**Index Sponsor**”) has been conducted by the Index Sponsor and BNP Paribas. Following this review, the Comité de Supervision Indice and Comité Opérationnel Indices of the Index Sponsor met on 29 August 2022 and concluded that the administration and calculation of the Impacted Indices should cease on or around 29 December 2022. As a result of this decision, no further index levels will be calculated or published by the Index Sponsor following such date of cessation.

Further information in respect of the Impacted Indices terminations is available on request from the Index Sponsor.

**Exane Derivatives SNC
Index Sponsor**

29 August 2022

PARIS

6 rue Ménars
75002 Paris
France
Tel: (+33) 1 44 95 40 00
Fax: (+33) 1 44 95 40 01

LONDON

10 Harewood avenue
London NW1 6AA
United-Kingdom
Tel: (+44) 207 039 9400

FRANKFURT

Senckenberganlage 19
60 325 Frankfurt
Germany
Tel: (+49) 69 42 72 97 300

GENÈVA

Rue du Rhône 80
1204 Geneva
Switzerland
Tel: (+41) 22 718 65 65

MADRID

Calle Emilio Vargas, 4
28043 Madrid
Spain
Tel: (+34) 91 114 83 00

MILAN

Milano Diamond Tower
Piazza Lina Bo Bardi 3
20124 Milan
Italy
Tel: (+39) 02 89 63 17 00

STOCKHOLM

Hovslagargatan 3
111 48 Stockholm
Sweden
Tel: (+46) 8 566 398 20

NEW YORK

Exane Inc
12 East 49th Street - 30th Floor
New York, NY 10017
United States
Tel: (+1) 21 2634 4990

SAN FRANCISCO

Exane Inc
201 Mission Street - Suite 2775
San Francisco, CA 94105
United States
Tel: (+1) 21 2710 9781/ (+1) 21 2634 4975

This document is issued by Exane Derivatives SNC (“Exane Derivatives”). Exane Derivatives is a member of the Exane Group (Exane SA and all its direct and indirect subsidiaries) and is an entity authorized by the Autorité de Contrôle Prudentiel et de Résolution as investment firm and regulated by the Autorité des Marchés Financiers and the Autorité de Contrôle Prudentiel et de Résolution. Exane Derivatives Paris, Geneva Branch, is an entity authorized as foreign securities dealer to the Swiss Financial Market Supervisory Authority (FINMA). The Milan Branch of Exane Derivatives is also authorized by the Autorité de Contrôle Prudentiel et de Résolution and by the Bank of Italy to provide certain investment service in freedom of establishment.

All information contained in this document has been compiled from sources believed to be reliable. However, no representation or warranty, expressed or implied, can be made with respect to the completeness or accuracy of its contents. The opinions and other information in this document can be amended without prior warning and Exane Derivatives is under no obligation to update them. The content of this document is for information purposes only. Exane Derivatives is not soliciting an action based upon it, and under no circumstances is it to be used or considered as an offer, invitation, solicitation or recommendation to buy or sell any of the financial instruments described herein. This document does not in any way intend to provide a comprehensive analysis of the securities, markets and trends described.

This document is provided solely for the information of eligible counterparties or professional investors who are expected to make their own investment decisions without undue reliance on this report. Investors are invited to make their own independent decision as to whether a financial instrument or whether investing in the financial instruments described herein is proper, suitable or appropriate based on their own judgment and upon the advice of any relevant and independent advisors they have consulted. Exane Derivatives accepts no liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

Figures included in this document may relate to past performances. Past performance is not a reliable indicator of future performance. Fluctuations in foreign exchange rates can have a negative impact on the value, price or returns of the products discussed in this report.

Recipients should be aware that Exane Derivatives and/or any entity of the Exane Group can hold, or have held, interests, or long or short positions in the financial instruments described in this document and, at any time, can buy and/or sell these instruments for its own account or for third parties, or can make, or have acted in a market or as market maker with respect to the securities mentioned in the report. In addition, Exane Derivatives and/or any entity of the Exane Group can have, or have had, a business relationship with the companies mentioned, or supply and have supplied services such as corporate financing, capital markets or other types of services.

This document is produced on behalf of Exane Derivatives and is solely for the private information of the recipients. The contents of this document cannot be reproduced, in full or in part, or distributed to third parties, without prior written approval of Exane Derivatives. Those persons who come into possession of the present document are requested by Exane Derivatives to inquire about of, and comply with, all the applicable rules and regulations relating to the possession or distribution of informational documents of this type.

This document is a marketing communication. This document has not been prepared in accordance with regulatory provisions designed to promote the independence of investment research, and Exane Derivatives is not subject to the ban on entering into transactions in the instrument in question prior to the release of the marketing communication.